Diabetic Foot Ulcer Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight

DelveInsight's, "Diabetic Foot Ulcer Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Diabetic Foot Ulcer pipeline landscape. It covers the Diabetic Foot Ulcer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Foot Ulcer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight's comprehensive Diabetic Foot Ulcer Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ [https://www.delveinsight.com/sample-request/diabetic-foot-ulcers-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Diabetic Foot Ulcer Pipeline Report

* On January 23, 2026- BioLab Holdings conducted a study is a multicenter, prospective, controlled modified multi-platform trial assessing the efficacy of human placental membrane products and standard of care in the management of nonhealing diabetic foot ulcers and venous leg ulcers.
* On January 20, 2026- Rion Inc. announced a Phase 2a study is to evaluate the safety and efficacy of PEP-TISSEEL+ Standard of Care (SOC) compared to SOC only treatment in up to 60 subjects (30 subjects PEP-TISSEEL + SOC and 30 subjects SOC only), specifically for the treatment of their non-healing DFU.
* DelveInsight's Diabetic Foot Ulcer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Diabetic Foot Ulcer treatment.
* The leading Diabetic Foot Ulcer Companies such as Energenesis Biomedical Co., Ltd, Microbion Corporation , Rion Inc., Aurealis Oy, BioTissue Holdings, Inc, Technophage, SA, Biocomposites Ltd, PolarityTE, NOxy Health Products, LLC, Cytora Ltd., Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd., Anterogen Co., Ltd., Cell2Cure ApS, Lakewood-Amedex Inc, FibroBiologic s and others.
* Promising Diabetic Foot Ulcer Therapies such as Biochaperone PDGF-BB Low dose, Santyl, Tegaderm Hydrogel, ofloxacin, MSI-78, ofloxacin, AUP1602-C, BB-101 and others.

Access DelveInsight's in-depth Diabetic Foot Ulcer Pipeline Analysis for a closer look at promising breakthroughs @ Diabetic Foot Ulcer Clinical Trials and Studies [https://www.delveinsight.com/sample-request/diabetic-foot-ulcers-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Diabetic Foot Ulcer Emerging Drugs Profile

* ENERGI-F703 GEL: Energenesis Biomedical Co., Ltd.

ENERGI-F703 is a gel for external use accelerating the healing of diabetes-caused wounds, mainly by activating AMPK inside cells to boost the density of ATP, energy molecules, in tissues near the wounds. Cellular and animal tests show that the application of ENERGI-F703 can produce various effects. It can reduce the inflammation of endothelial cells of blood vessels. It can accelerate the fibrosis of fibroblasts in the skin of wounds and increase the deposition of collagen and the formation of granulation tissues. It can also speed up the healing of wounds by promoting the migration of epithelia cells in the skin of wounds. Via the utilization of a diabetic model mouse, it's proven that the application of ENERGI-F703 gel on wounds can accelerate the healing of wounds. Currently, the drug is in the Phase III stage of its development for the treatment of Diabetic Foot Ulcers.

* Topical Pravibismane: Microbion Corporation

Topically administered pravibismane, comprised of a suspension of pravibismane in a hydrogel formulation (MBN-101), has the potential to provide important advantages for the treatment of DFIs, including the dual broad-spectrum antimicrobial and anti-biofilm effects of the drug and its ability to kill common antibiotic resistant species. Standard of care is frequently ineffective in treating these patients. Ineffective management of DFIs has the potential to result in lower limb amputations; high treatment costs; additional hospitalizations; and the need for long courses of systemic antibiotics. Additionally, Qualified Infectious Disease Product (QIDP) designation and Fast Track status have been also granted for topical pravibismane (MBN-101) by the US FDA for adjunctive treatment of moderate and severe diabetic foot ulcer infections. Currently, the drug is in Phase II stage of its development for the treatment of Diabetic Foot Ulcers.

* PEP (Purified Exosome Product): Rion Inc.

RION's Purified Exosome Product Trademark (PEP Trademark ) is a shelf-stable product in a lyophilized powder derived from human platelets that contains stabilized platelet-derived regenerative exosomes. PEP Trademark is an exosome therapeutic that is designed to promote cell growth and formation of new blood vessels, while also reducing inflammation and protecting cells. Exosomes are nanoscale extracellular vesicles, secreted by cells that act as carriers of biological messages. These messages, composed of proteins, nucleic acids, and lipids, are transported from their cell of origin to other cells, orchestrating a multitude of processes that underpin health, disease, and the regenerative capabilities of the body. RION harnesses the unique regenerative properties of platelets, an ideal source of regenerative exosomes, due to their natural role in healing and regeneration. Currently, the drug is in the Phase II stage of its development for the treatment of Diabetic Foot Ulcers.

* AUP1602-C: Aurealis Oy

AUP-16 is a genetically engineered Lactococcus Cremoris, a non-pathogenic, probiotic bacteria, expressing human basic fibroblast growth factor (FGF-2, bFGF), interleukin-4 (IL-4) and macrophage colony-stimulating factor (CSF-1, mCSF), an all in one product and accepted as one active pharmaceutical ingredient from regulatory perspective. AUP-16 is topically applied on chronic wounds and covered by wound dressing like in diabetic foot ulcers, venous leg ulcers or other ulcer types. In the wound AUP-16 acts as millions of bioreactors producing the therapeutic proteins, which are designed to halt chronic inflammation in the wound, induce growth of new blood vessels, and promote granulation tissue formation and skin re-epithelization, all in one product. Currently, the drug is in Phase II stage of its development for the treatment of Diabetic Foot Ulcers.

The Diabetic Foot Ulcer Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Foot Ulcer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Foot Ulcer Treatment.
* Diabetic Foot Ulcer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Diabetic Foot Ulcer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Foot Ulcer market.

Explore DelveInsight's expert-driven report today! @ Diabetic Foot Ulcer Unmet Needs [https://www.delveinsight.com/sample-request/diabetic-foot-ulcers-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Diabetic Foot Ulcer Companies

Energenesis Biomedical Co., Ltd, Microbion Corporation , Rion Inc., Aurealis Oy, BioTissue Holdings, Inc, Technophage, SA, Biocomposites Ltd, PolarityTE, NOxy Health Products, LLC, Cytora Ltd., Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd., Anterogen Co., Ltd., Cell2Cure ApS, Lakewood-Amedex Inc, FibroBiologic s and others.

Diabetic Foot Ulcer Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Diabetic Foot Ulcer Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Download DelveInsight's latest report to gain strategic insights into upcoming Therapies and key Developments @ Diabetic Foot Ulcer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/diabetic-foot-ulcers-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Diabetic Foot Ulcer Pipeline Report

* Coverage- Global

* Diabetic Foot Ulcer Companies- Energenesis Biomedical Co., Ltd, Microbion Corporation , Rion Inc., Aurealis Oy, BioTissue Holdings, Inc, Technophage, SA, Biocomposites Ltd, PolarityTE, NOxy Health Products, LLC, Cytora Ltd., Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd., Anterogen Co., Ltd., Cell2Cure ApS, Lakewood-Amedex Inc, FibroBiologic s and others.

* Diabetic Foot Ulcer Therapies- Biochaperone PDGF-BB Low dose, Santyl, Tegaderm Hydrogel, ofloxacin, MSI-78, ofloxacin, AUP1602-C, BB-101 and others.
* Diabetic Foot Ulcer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Diabetic Foot Ulcer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight's exclusive Diabetic Foot Ulcer Pipeline Report-access it now! @ Diabetic Foot Ulcer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/diabetic-foot-ulcers-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Diabetic Foot Ulcers: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Diabetic Foot Ulcers - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* ENERGI-F703 GEL: Energenesis Biomedical Co., Ltd.
* Mid Stage Products (Phase II)
* PEP (Purified Exosome Product): Rion Inc.
* Early Stage Products (Phase I)
* Preclinical/Discovery Stage Products
* Inactive Products
* Diabetic Foot Ulcers Key Companies
* Diabetic Foot Ulcers Key Products
* Diabetic Foot Ulcers- Unmet Needs
* Diabetic Foot Ulcers- Market Drivers and Barriers
* Diabetic Foot Ulcers- Future Perspectives and Conclusion
* Diabetic Foot Ulcers Analyst Views
* Diabetic Foot Ulcers Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diabetic-foot-ulcer-treatment-pipeline-shows-strong-momentum-as-20-pharma-companies-in-the-race-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.